INTRODUCTION
Ingenol mebutate (a macrocyclic diterpene ester, PEP005, 0.015%) derives from the sap of the plant Euphorbia peplus. This herb has been used of old as a traditional remedy for skin cancers. Ingenol mebutate is currently an US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recognized field-directed treatment for actinic keratosis [1, 2] . Ingenol mebutate activates a broad range of protein kinase C (PKC) (a, b, c, d, e, g and h) isoenzymes [3] . Direct pro-apoptotic effects of this drug have been demonstrated in several malignant cells, including melanoma cell lines. Micromolar concentrations of ingenol mebutate are required to kill melanoma cells via PKC-independent secondary necrosis [3] . Topical application of ingenol mebutate was revealed as being effective for human and murine melanoma in mouse models [3] . In transformed keratinocytes, ingenol mebutate leads to cell death. Furthermore, ingenol mebutate promotes an inflammatory infiltrate that kills remaining tumor cells. It has been demonstrated that ingenol mebutate does not mediate cytotoxicity by a simple lytic, necrotic mechanism, but activates distinct processes involving multiple cell organelles in a cell-type and differentiation-dependent manner [4] . In vitro experiments revealed epidermal cell death, acute inflammation, recruitment of neutrophils, hemorrhage, and eschar formation when ingenol mebutate was tested on keratinocytic cell lines and squamous cell cancer cell lines [5, 6] . Currently, the action mechanism of ingenol mebutate is divided into three consecutive steps; (1) a direct effect of the drug on the initial cancer accompanied by an in situ production of pro-inflammatory cytokines, (2) neutrophil infiltration, and (3) induction of tumor-reactive antibodies, diminishing potential relapses by antibodydependent neutrophil cytotoxicity [3] .
However, as far as the authors are aware, no published data are available on a potential effect of ingenol mebutate on in vivo melanoma.
Melanoma in situ (MIS) is the most superficial form of melanoma [7, 8] 
CASE REPORT
A 91-year-old woman presented with 2 biopsyproven recurrent MISs in the direct vicinity of a scar on her right cheek ( (Fig. 3) . A cutaneous biopsy proved the absence of residual MIS on histology (Fig. 4) and on using immunohistochemistry with NKI-C3, S100a, HMB45 and Melan A (DAKO, Glostrup, Denmark) (Fig. 5) . The local tolerance of the treatment was acceptable for the patient and no systemic signs were observed. After 6 months of follow-up the patient was still free of MIS recurrence.
DISCUSSION
Standard care for MIS is surgical excision or Mohs surgery respecting a margin of 5-9 mm of clinically non-involved healthy skin [7] . However, alternative treatment options for MIS are sometimes required for different reasons.
Either the patient refuses excisional surgery or surgery is no longer recommended due to morbidity and/or cosmetic considerations [8] . Furthermore, older age, multiple previous surgical procedures, medical comorbidities may preclude from surgery. The non-invasive treatment options for MIS include local radiation therapy and topical immunotherapy.
Occasionally cryotherapy or cryosurgery could also be advocated. Radiation therapy uses either Grenz rays or soft X-rays. Although published cure rates achieving 86% to 95%, it remains an uncommonly used treatment option for MIS in poor candidates for surgery. Imiquimod is a synthetic imidazoquinoline amine and acts as a toll-like receptor (TLR) agonist on TLR7 and TLR8 [7] [8] [9] [10] [11] . This topical immunomodulator increases, after binding to the TLR's, the endogenous production of interferon-alpha, exhibiting anticancer properties, interleukins (ILs) 6 and 12, as well as tumor necrosis factor alpha [7, 8] . Evidencebased medicine data on imiquimod and MIS are scarce. Most publications deal with small case series and case reports [6] . A recent metaanalysis showed an average clearance rate of 91% with a histological proof [7] . However, the follow-up periods were usually short, the ''negative biopsy'' did not preclude persisting areas of MIS and particular attention should be given to invasive melanoma progression after an initial superficial tumor clearing.
There is no standard recommendation on dosing and application protocols of imiquimod and adaptations are often required to minimize the local adverse reactions, consisting of moderate to severe erythema, crusting, and sometimes oozing, usually occurring after 2-3 weeks of treatment. Systemic effects may sometimes be observed in the form of flu-like symptoms with fever, headache, hyperesthesia, myalgia and fatigue.
In sum, the long-term cure rates of imiquimod are questionable [7] and caution is advocated not to fail a subsequent diagnosis of residual or recurrent invasive melanoma [7] . This case report suggests that in some 
CONCLUSION
Ingenol mebutate merits to be considered as an alternative treatment option for MIS in selected 
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